Psoriasis is a chronic inflammatory skin disease affecting 2% to 3% of the world population. 1 Psoriasis is thought to result from impaired communication between keratinocytes and immune cells, including T cells, dendritic cells, and neutrophils, because of genetic and environmental factors. 2, 3 In psoriatic skin lesions, infiltrating immune cells produce inflammatory mediators that lead to altered differentiation, hyperproliferation, and activation of keratinocytes, resulting in epidermal hyperplasia. 2, 3 Activated keratinocytes produce inflammatory cytokines and chemokines, leading to further recruitment and activation of immune cells and resulting in a vicious circle of chronic inflammation.
2,3 IL-17, which is produced by T H 17 cells and other cell types, has been shown to play a central role in psoriasis because it induces the production of proinflammatory chemokines, cytokines, and antimicrobial peptides in keratinocytes. [4] [5] [6] The importance of the IL-17 signaling pathway in patients with psoriasis is evidenced by the almost complete clearance of the disease by biological treatments targeting this pathway. [4] [5] [6] Psoriasis has a strong genetic component, and genome-wide association studies have identified a growing number of psoriasis susceptibility genes involved in immunity and keratinocyte functions. 7 Although the majority of psoriasis-associated regions identified by using genome-wide association studies are located in noncoding DNA, 7 little is known about the contribution of specific noncoding RNA genes to psoriasis susceptibility.
MicroRNAs (miRNAs) are short noncoding RNAs that suppress the expression of protein-coding genes at the posttranscriptional level. 8 Each miRNA regulates dozens to hundreds of target genes, which are often functionally related. 8 In patients with psoriasis, early studies identified deregulation of a set of miRNAs in skin lesions, 9, 10 and subsequent work showed that several miRNAs deregulated in patients with psoriasis regulate important keratinocyte and leukocyte functions and contribute to defective keratinocyte/immune cell crosstalk. [10] [11] [12] [13] [14] [15] [16] However, the contribution of genetic variations affecting miRNA function to psoriasis has remained largely unknown. 17 Here we identify a protective association of a functional polymorphism in the microRNA-146a (miR-146a) gene (rs2910164) with psoriasis, which protects against early disease onset in particular. Subsequent functional studies revealed that miR-146a defines the sensitivity of keratinocytes to IL-17A and acts as a brake on psoriasis-like skin inflammation. miR-146a-deficient mice present with early onset and incomplete healing of psoriasiform skin lesions in the imiquimod-induced psoriasis model, whereas in vivo delivery of miR-146a mimic into mouse skin reduces disease pathology.
METHODS Patients
DNA was extracted from peripheral blood samples collected from 1546 patients with psoriasis and 1526 ethnically matched control subjects (see Table E1 in this article's Online Repository at www.jacionline.org). Only cases and control subjects of white origin based on ethnicity single nucleotide polymorphism (SNP) genotyping were included. 18 Four-millimeter punch biopsy specimens were collected from lesional skin of patients with psoriasis having the miR-146a rs2910164-CC (n 5 4) or rs2910164-GG (n 5 4) genotype. Patients and control subjects provided written informed consent, and the study was approved by the regional ethics committee and performed according to the Declaration of Helsinki Principles.
Genetic analysis
The analysis of genetic association of miR-146a rs2910164 and psoriasis was carried out on 1546 patients with psoriasis and 1526 control subjects (see Table E1 ). The rs2910164 SNP (AssayID; C_15946974_10; Applied Biosystems by Life Technologies, Foster City, Calif) was genotyped on the QuantStudio 7 Flex Instrument (Thermo Fisher Scientific, Carlsbad, Calif) by using allele-specific TaqMan MGB probes. HLA-C*06:02 typing was carried out, as previously described. 19 Mice and the imiquimod model of psoriasis-like skin inflammation
Female B6/miR-146a 2/2 and wild-type (WT) C57BL/6J mice at 8 weeks of age were procured from the Jackson Laboratory (Bar Harbor, Me) and Charles River (Wilmington, Mass), respectively. For the early phase of disease development, a daily topical dose of 31.25 mg of imiquimod (Aldara cream; Meda Pharmaceuticals, Somerset, NJ) was applied on the ears of miR-146a 2/2 and WT mice for 3 consecutive days, and mice were killed at day 4. To characterize disease resolution, a daily topical dose of 62.5 mg (5%) of imiquimod (Aldara cream) was applied on the shaved back skin for 6 consecutive days, and mice were killed on day 7. Control mice were treated with the same amount of vehicle cream. Clinical scores were assessed by 3 independent researchers to assign a score of 0 to 4 (0, none; 1, mild; 2, moderate; 3, severe; and 4, very severe) for erythema, scaling, and thickness. All animal experiments were approved by local ethics committee of Stockholm, Sweden (Swedish Board of Agriculture). Allele association was performed in PLINK with logistic regression, with sex as the covariate. Genotype and recessive association models were performed by using a generalized linear model, as implemented in the R software package, version 3.1.3. Subjects with the G, GG, and GG/GC genotypes for rs2910164 were set as baseline. Stratification by HLA-C*06 only considering HLA-C*06-negative status and age at onset was performed by using a generalized linear model as implemented in R software package, version 3.1.3. Subjects with the GG/GC genotypes for rs2910164 were set as baseline. In vivo delivery of microRNA mimics 
Statistical analysis
Allele association between rs2910164 and psoriasis was analyzed in PLINK v1.07 by using logistic regression, with sex as the covariate. 20 Genotype and recessive association models, as well as stratification by age and independent association for miR-146a by using subjects with rs2910164-GG/GC and negative for HLA-C*06 as the reference group, was calculated by using R v3. 
RESULTS

A functional polymorphism in the miR-146a gene is associated with psoriasis
The G-to-C polymorphism rs2910164 is located within the sequence of the miR-146a precursor, which leads to a change from a G:U pair to a C:U mismatch in its stem region, resulting in altered levels of miR-146a. 21 Here we investigated the relationship between this functional miR-146a polymorphism and psoriasis in a Swedish psoriasis cohort (n 5 1546) and healthy control subjects (n 5 1526, see Table E1 ). The frequency of the variant C allele was 0.20 in patients with psoriasis and 0.21 in control subjects. Even though no significant association between psoriasis and the miR-146a rs2910164-C allele was found (P 5 .10; odds ratio [OR], 0.90; CI 95%, 0.80-1.02; Table I ), genotype analysis revealed a trend showing that patients with the CC genotype were marginally protected from psoriasis compared with those with GC or GG genotypes (P 5 .03; OR, 0.68; 95% CI, 0.47-0.97). However, when stratifying for HLA-C*06, the main risk gene for psoriasis, 7 we found a strong protective association for the CC genotype in HLA-C*06-negative patients (P 5 .008; OR, 0.53; 95% CI, 0.33-0.84; Table I ). Moreover, analysis of genotype frequencies in patients with early (<40 years) versus late onset (>40 years) of the disease revealed that the presence of the rs2910164-CC genotype protects against early onset of psoriasis (P 5 .02; OR, 0.36; 95% CI, 0.14-0.84; see Table E2 in this article's Online Repository at www.jacionline.org). When considering only patients with early onset (<40 years) and stratified for HLA-C*06, the association was even more significant (P 5 .001; OR, 0.29; 95% CI, 0.13-0.58; see Table E2 ). We observed no deviation from Hardy-Weinberg equilibrium for any of the markers (P > .05). Duplicates did not reveal any genotyping errors.
miR-146a is overexpressed in psoriatic skin lesions, 13 and in situ hybridization showed that it is overexpressed in epidermal cells in psoriatic lesions compared with healthy skin (see Fig  E1 in this article's Online Repository at www.jacionline.org). Interestingly, quantitative PCR (qPCR) results on sorted epidermal cells revealed that the miR-146a level was significantly higher in patients with psoriasis with the CC genotype compared with those with the GG genotype (see Fig E2 in this article's Online Repository at www.jacionline.org). Altogether, these data indicate a strong protective effect of the miR-146a rs2910164-CC genotype in patients with psoriasis, in particular against early onset of the disease.
miR-146a deficiency leads to earlier disease onset and more severe skin inflammation with amplified epidermal activation in the imiquimod-induced model of psoriasis Imiquimod-induced skin inflammation is a well-characterized mouse model for psoriasis. 22 To characterize the role of miR-146a during the early phase of disease development, topical imiquimod (Aldara cream) was applied on the ears of miR-146a 2/2 and WT mice for 3 consecutive days (Fig 1, A) . We used young mice (6-8 weeks of age) because miR-146a 2/2 mice are phenotypically normal at this age and do not show an inflammatory phenotype. 23 
miR-146a
2/2 mice had an earlier onset of the disease, with significantly increased ear thickness as early as day 3, whereas WT mice showed no signs of skin inflammation until day 4 (Fig 1,  B) . At day 4, miR-146a 2/2 mice had more pronounced skin inflammation and significantly increased ear thickness compared with WT mice (Fig 1, B and C). Vehicle-treated control mice did not show any sign of skin inflammation (see Fig E3 in this article's Online Repository at www.jacionline.org). Histologic analysis showed that imiquimod treatment induced epidermal thickening, which was further enhanced in miR-146a-deficient mice (Fig 1, C  and D) . Moreover, increased epidermal hyperproliferation in the imiquimod-treated skin of miR-146a-deficient mice was observed based on a significantly increased number of Ki67 1 epidermal cells (Fig 1, E) . Interestingly, epidermal thickness and Ki67 expression were slightly, although not significantly, increased in untreated miR-146a 2/2 mice compared with WT mice (Fig 1, C and E) . Immunohistochemistry (IHC) analyses for the neutrophil marker Gr-1 showed that imiquimod treatment led to an increase in the number of Gr-1 1 cells in the skin, and a significantly higher increase was observed in miR-146a 2/2 mice compared with that seen in WT mice, indicating increased infiltration of neutrophil granulocytes (Fig 1, F) .
We next aimed to identify the molecular differences in psoriasis-like skin inflammation in WT and miR-146 2/2 mice. Expression profiling identified 497 differentially expressed genes C and D, Hematoxylin and eosin staining of ear sections from miR-146a 2/2 and WT mice and quantification of epidermal thickening on hematoxylin and eosin-stained ears. E, IHC on ear sections from miR-146a
and WT mice for Ki67 (left) and quantification (right). F, Quantification of Gr-1 1 cells in ear samples (n 5 4). G, GSEA of epidermis of patients with psoriasis (left panel) 26 or genes induced by IL-17 in keratinocytes (right panel) 27, 28 in imiquimod-treated miR-146a 2/2 mice. H, Microarray analysis of RNA from wild-type and miR-146a 2/2 mice after imiquimod induction. I, qPCR analyses of miR-146a, S100a7, S100a8 and S100a9, Krt16, Il1b, and Cxcr2 in mouse ear samples (n 5 6). Scale bar 5 100 mm. *P < .05, **P < .01, and ***P < .001. (DEGs) between WT and miR-146a 2/2 mice on imiquimod treatment (see Table E3 in this article's Online Repository at www.jacionline.org). Imiquimod-treated skin of WT and miR-146a 2/2 mice was clearly differentiated by using unsupervised hierarchical clustering (see Figs E4 and E5 in this article's Online Repository at www.jacionline.org). The DEGs included several well-known genes related to keratinocyte activation with roles in the pathogenesis of psoriasis, including S100 proteins, chemokines, IL-1-regulated genes, and proliferationrelated genes (Ki67; see Figs E4 and E5 and Table E3 ). Indeed, gene ontology analysis of DEGs revealed that genes encoding for proteins related to keratinocyte activation showed differential expression in the imiquimod-induced skin lesions of miR-146a 2/2 mice compared with those in WT mice (see Figs E4, B, and E5, B) . Gene network analysis identified TNF receptor-associated factor 6 (TRAF6) and epidermal growth factor receptor (EGFR), 2 known direct targets of miR-146a, 24, 25 as hubs in the deregulated gene networks, suggesting that many of the transcriptomic changes could be explained through these 2 target genes (see Fig E4, C) . The observation that genes with the highest upregulation in skin lesions in miR-146a
mice showed a keratinocyte-specific expression pattern (S100a8, S100a9, Krt6b, Klk10, Sprr2e, and Il1a) suggested that exacerbated skin inflammation in miR-146a 2/2 mice could be explained by increased epidermal activation.
To determine whether the more severe inflammation observed on miR-146a 2/2 mice was due to changes primarily in the epidermal or dermal compartment, we performed gene set enrichment analysis (GSEA) using gene sets obtained from previous investigations identifying the dermal and epidermal transcriptome signature of human psoriasis. 26 GSEA defined a significant enrichment of epidermal (Fig 1, G) but not dermal psoriasis-associated genes among DEGs in the skin lesions of miR-146a 2/2 mice, suggesting that the exacerbated pathology is mainly due to epidermal changes. Moreover, genes previously shown to be induced by IL-17 in keratinocytes 5, 27, 28 were significantly enriched in skin lesions of miR-146a 2/2 mice (Fig 1, G) , including cytokines, chemokines, antimicrobial peptides, and genes encoding proteins related to keratinocyte proliferation and differentiation (Fig 1, H) .
Array data were confirmed by using qPCR analysis (Fig 1, I ). miR-146a was induced by imiquimod in WT mice, and as expected, miR-146a was not detected in the skin of miR-146a 2/2 mice (Fig 1, I) . Levels of the antimicrobial peptide gene family S100s (S100a7, S100a8, and S100a9), keratin 16 (Krt16), a marker of keratinocyte hyperproliferation, the proinflammatory cytokine Il1b, and Cxcr2, a chemokine receptor preferentially expressed by neutrophils, were induced by imiquimod and showed further enhanced induction in miR-146a 2/2 mice on imiquimod treatment (Fig 1, I ). Taken together, miR-146a deficiency leads to earlier disease onset, with increased activation of keratinocytes, and in particular, increased activity of the IL-17 signaling pathway.
miR-146a acts as a negative feedback on IL-17-induced inflammatory responses in keratinocytes
Primary keratinocytes were isolated from miR-146a 2/2 and WT mice, cultured, and treated with IL-17A to assess keratinocyte activation in miR-146a-deficient mice. qPCR analysis showed a significantly higher induction of Cxcl1, a neutrophil chemoattractant, 4 on IL-17A treatment in miR-146a
2/2 compared with WT keratinocytes (Fig 2, A) . Similarly, significantly higher induction of the T-cell chemoattractant Ccl20 was observed in IL-17A-treated miR-146a 2/2 keratinocytes (see Fig E6, A, in this article's Online Repository at www.jacionline.org).
Next, we tested whether the observed effects of miR-146a are limited to CXCL1 and CCL20 or whether they mirror a more general effect of miR-146a on the IL-17 pathway in keratinocytes. To this end, GSEA of DEGs identified by using transcriptomic profiling data in human keratinocytes overexpressing miR-146a was performed. 29 GSEA revealed significant enrichment of IL-17 pathway genes (including those encoding CXCL1, IL-8, CCL20, and IL-1b), suggesting that miR-146a preferentially regulates the IL-17 pathway in keratinocytes (Fig 2, B) .
To dissect the role of miR-146a in the IL-17 response of keratinocytes, we examined the kinetics of the expressions of miR-146a and IL-8, a functional homologue of mouse Cxcl1, on IL-17A treatment in human keratinocytes (Fig 2, C) . IL-17A induced the expression of IL-8, which began to be detectable 3 hours after stimulation, reached a plateau at 6 hours, and then began to decrease. In contrast, IL-17A treatment resulted in a detectable increase of miR-146a expression first at 6 hours, which then continued to increase, even 24 and 48 hours after stimulation.
Time kinetics suggested that miR-146a is involved in the regulation of IL-17-induced inflammatory responses of keratinocytes. To test this, keratinocytes were treated with increasing concentrations of IL-17A (5-200 ng/mL) in combination with ectopic overexpression of miR-146a. qPCR and ELISA results demonstrated that miR-146a dramatically suppressed IL-17A-mediated induction of IL-8 (Fig 2, D) . miR-146a overexpression completely prevented IL-8 induction by lower concentrations of IL-17A, but even at higher concentrations, a strong reduction in induction was observed (Fig 2, D) , indicating decreased sensitivity of keratinocytes to respond to IL-17A (Fig 2, D) . In the next step we investigated the hypothesis that baseline miR-146a in keratinocytes can define the strength of the IL-17-induced inflammatory response. Inhibition of endogenous miR-146a in human keratinocytes led to a significant increase in the baseline and IL-17A-induced expression and secretion of IL-8 (Fig 2, E) , miR-146a mimics or scramble control (left) and heat map for selected IL-17-regulated genes (right). C, qPCR for miR-146a and IL-8 in human keratinocytes treated with 100 ng/mL IL-17A. D and E, qPCR (left) and ELISA (right) analysis of IL-8 in human keratinocytes on miR-146a overexpression/inhibition, followed by treatment with IL-17A (at the indicated doses for 6 hours [left] or 100 ng/mL for 24 hours [right]). F, Western blot analysis of phosphorylated and total p65 in keratinocytes transfected with miR-146a mimic or miR-146a inhibitor, followed by treatment with 100 ng/mL IL-17A at indicated time points. G, Immunofluorescence analysis of p65 in primary human keratinocytes transfected with miR-146a mimics or inhibitors, followed by treatment with 100 ng/mL IL-17A for 40 minutes. Scale bar 5 100 mm. *P < .05, **P < .01, and ***P < .001. = J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 2 which is in agreement with our observations in miR-146a 2/2 mouse keratinocytes (Fig 2, A) . Induction of IL-8 by IL-17A was concentration dependent, with a median effective concentration of 59.9 ng/mL in control keratinocytes (see Fig E7 in this article's Online Repository at www.jacionline.org), whereas the median effective concentration was decreased to 32.9 ng/mL in miR-146a inhibitor-treated keratinocytes (P 5 .0073), indicating that the inhibition of miR-146a led to an approximately doubled sensitivity of keratinocytes to IL-17A stimulation (see Fig  E7) . qPCR analysis of CCL20 in IL-17A-treated keratinocytes showed similar results (see Fig E6, B and C) . Overexpression or inhibition of miR-146a in keratinocytes was confirmed with qPCR (see Fig E8 in this article' s Online Repository at www. jacionline.org).
A key component of IL-17 signal transduction is the nuclear factor kB pathway, activation of which is indicated by nuclear translocation and phosphorylation of the p65 subunit. Protein immunoblotting for phosphorylated and total p65 showed a strong induction in phosphorylation of p65 on IL-17A treatment (Fig 2,  F) , which is in agreement with previous results. 4 Inhibition of mir-146a increased, whereas overexpression of miR-146a decreased, phosphorylation of p65 in keratinocytes (Fig 2, F) . Likewise, immunofluorescence analysis showed nuclear translocation of p65 after IL-17A treatment (Fig 2, G) , which was further enhanced by miR-146a inhibition; in contrast, miR-146a overexpression inhibited IL-17A-induced nuclear translocation of p65 (Fig 2, G) .
miR-146a suppresses the neutrophil chemoattractant capacity of keratinocytes
Keratinocyte-derived IL-8/CXCL8 and CXCL1 can function as chemoattractants for neutrophil granulocytes, which are present in psoriatic lesions. 2 To determine whether miR-146a can affect the neutrophil-attracting ability of keratinocytes, miR-146a was inhibited/overexpressed in human keratinocytes, followed by IL-17A stimulation, and conditioned medium from these cells was used in neutrophil migration assays (Fig 3, A) . Treatment of keratinocytes with IL-17A led to increased neutrophil chemotaxis toward the conditioned medium (Fig 3, B) . In accordance with the increased expression of CXCL1 and IL-8 in miR-146a 2/2 mouse keratinocytes and miR-146a inhibitor-treated human keratinocytes, inhibition of endogenous miR-146a led to a further increase in the number of migrated neutrophils (Fig 3, B) . In contrast, overexpression of miR-146a led to a significant decrease in numbers of migrated neutrophils (Fig 3, B) . In line with the observed effect of miR-146a on baseline IL-8 production (Fig 2, D and E) , overexpression/inhibition of miR-146a in untreated keratinocytes also affected their neutrophil chemoattractant capacity (Fig 3, B) . Delayed and incomplete healing of psoriasis-like skin inflammation in miR-146a 2/2 mice after discontinuation of imiquimod treatment
The failure of resolution of inflammation after an inflammatory challenge is a hallmark of chronic inflammation. Because our results indicated a role for miR-146a as a negative feedback regulator of IL-17 signaling, we hypothesized that miR-146a contributes to the restoration of homeostasis in the skin. To test this, WT and miR-146a 2/2 mice were treated topically with imiquimod for 6 consecutive days, and we continued to observe Quantification of Gr-1 1 cells in skin samples from miR-146a 2/2 and WT mice (n 5 4). I, qPCR for miR-146a, Il1b, Ccl20, and Cxcl1 in back skin of mice (n 5 6). Scale bar 5 100 mm. *P < .05, **P < .01, and ***P < .001. the mice during the resolution phase of the disease after discontinuation of imiquimod treatment (Fig 4, A) . Although both miR146a 2/2 and WT mice had psoriasiform skin disease with erythema and scaling and thickening of the skin (Fig 4, B and C) , miR-146a deficiency led to a pronounced increase in disease severity, as well as delayed healing after discontinuation of imiquimod treatment (Fig 4, B and C) . Erythema, scaling, and skin thickness was significantly increased in imiquimod-treated miR146a 2/2 mice compared with WT control mice (Fig 4, C) . After discontinuation of imiquimod treatment, the phenotype was improved in WT mice already at day 7, and complete healing with no detectable inflammatory pathology was observed by day 10 (Fig 4, B and C) . In miR-146a 2/2 mice the disease phenotype started to improve on day 8, and signs of skin inflammation were present even at day 10 (Fig 4, B and C) . Thus miR-146a is required for the resolution of skin inflammation on an inflammatory trigger.
For histologic and molecular characterization of disease resolution, additional WT and miR-146a 2/2 mice were treated topically with imiquimod for 6 consecutive days, and skin samples were obtained at day 7, when the disease starts to improve in WT mice (Fig 4, D) . Histologic and IHC analysis of the skin collected at day 7 confirmed delayed healing of skin inflammation in miR-146a 2/2 mice, showing a significantly thicker epidermis (Fig 4, E and F) and higher numbers of Ki67 1 cells (Fig 4, G ) compared with those in WT mice. Moreover, we observed an increased number of Gr-1 1 neutrophil granulocytes in the skin, indicating prolonged neutrophil infiltration (Fig 4, H) . qPCR analysis showed induction in miR-146a expression on imiquimod stimulation in skin of WT mice, with no detectable expression in miR-146a 2/2 mice (Fig 4, I) . Moreover, qPCR analysis of several IL-17 response genes (Il1b, Ccl20, and Cxcl1) showed increased expression in the skin of miR-146a 2/2 mice compared with that in WT mice at day 7 (Fig 4, I) , indicating prolonged activation of IL-17 signaling. Altogether, these results demonstrate a role for miR146a in the restoration of skin homeostasis after inflammatory challenge.
Local delivery of miR-146a alleviates psoriasiform skin inflammation
Because our data pointed to a suppressive effect of miR-146a on psoriasis-like skin inflammation, we next tested whether miR146a overexpression might have a therapeutic effect. To this end, miR-146a mimics were injected intradermally before and during imiquimod application, and samples were collected at day 4 ( Fig  5, A) . Laser-capture microdissection followed by qPCR analysis of miR-146a, as well as in situ hybridization for miR-146a, confirmed increased miR-146a levels in the epidermis on injection of miR-146a mimics (see Fig E9 in this article' s Online Repository at www.jacionline.org). Strikingly, local delivery of miR-146a mimics efficiently inhibited the development of psoriasiform skin disease manifestations, including erythema, thickness, and scaling (Fig 5, B) . Histologic and IHC analyses demonstrated that treatment with miR-146a mimics significantly reduced imiquimod-induced epidermal thickening (Fig 5, C) , with decreased numbers of proliferating keratinocytes, as assessed based on Ki67 expression (Fig 5, D) . Moreover, the number of infiltrating neutrophils was significantly decreased, as judged by means of IHC quantification of Gr-1 1 cells (Fig 5, E) . qPCR analysis confirmed overexpression of miR-146a on intradermal delivery of mimics, with 14-fold higher levels of miR-146a in mice injected with miR-146a mimics compared with scramble controls (Fig 5, F) . Levels of Il1b and the neutrophil marker Ly6G were significantly decreased in the skin of mice treated with miR-146a mimics (Fig 5, F) . In conclusion, local delivery of miR-146a mimics alleviates psoriasiform skin inflammation.
DISCUSSION
In recent years, genome-wide association studies have identified a growing number of psoriasis susceptibility loci. 7 Despite this progress, only about 25% of psoriasis heritability has been accounted for, suggesting that there are susceptibility factors that have been missed. 17, 30 Because the majority of the identified loci are in noncoding DNA, it has been speculated that genetic variations in functional RNAs, such as miRNAs, might contribute to psoriasis susceptibility. 17 Our findings showing a protective association of the functional polymorphism rs2910164 in the miR146a gene with psoriasis support that further investigation of the association of genetic variants in noncoding RNA genes and psoriasis is necessary.
Most genetic studies have analyzed a mixture of clinical subtypes and thus revealed risk genes that are shared by the majority of psoriasis phenotypes. However, psoriasis displays wide phenotypic variation, and genetic heterogeneity is likely to contribute to the observed clinical diversity; thus stratification of disease phenotypes might uncover new associations. In our study, although only a weak association between the miR-146a rs2910164 CC genotype with psoriasis was found in the unstratified cohort of patients with psoriasis, a strong protective association was found after stratification by HLA-C*06 status. Further stratification revealed that the protective effect of this SNP is even stronger for early-onset psoriasis.
The SNP rs2910164 is located in the stem region opposite to the mature miR-146a sequence, and the rarer C allele results in a mismatch in the pre-miRNA 31 and has been shown to directly affect the processing of the miRNA, leading to altered levels of the mature miRNA. 21 This SNP has been shown to be associated with several autoimmune diseases. 32 In line with our findings, in the Chinese Han population, where the G allele is the minor allele, the GG/CG genotype was found be associated with increased risk of psoriasis. 24 Interestingly, the protective allele is a minor allele in the white population in which the prevalence of psoriasis is much higher (3% to 4%) 1 than in the Chinese Han population (<1%), 24 in which it represents the major allele. The different allele frequencies in rs2910164 might contribute to the genetic basis of variation in the prevalence of psoriasis among subjects of different ethnicities, in addition to other genetic and environmental factors.
Genetic deletion of miR-146a resulted in altered disease course, with an earlier onset and delayed healing in the imiquimod-induced mouse model of psoriasis. Earlier onset of the disease in miR-146a-deficient mice might be paralleled by the protective genetic association with early disease onset and suggests a role for miR-146a, setting the threshold for initiation of the disease. Moreover, miR-146a-deficient mice showed increased severity of psoriasis-like skin inflammation, with increased skin thickness, epidermal hyperproliferation, production of chemokines and host defense genes, and infiltration of neutrophil granulocytes. Increased production of keratinocytederived mediators was mainly responsible for the exacerbated phenotype, as evidenced by the significant enrichment of psoriasis-associated epidermal genes among the genes differentially expressed in the skin lesions of miR-146a-deficient mice. Although the possibility that the known effects of miR-146a in the immune system partially contribute to the observed phenotype cannot be excluded, our results clearly establish increased epidermal activation on miR-146a deletion.
The imiquimod mouse model of psoriasis is an acute model in which skin inflammation is induced during the course of imiquimod application for several days, and thereafter, inflammation decreases, even if imiquimod application is continued. 22 Strikingly, the resolution of the disease was impaired in miR-146a-deficient mice because healing was incomplete until 10 days. This suggests a role for miR-146a in disease resolution by shutting down inflammatory responses in the skin.
The IL-23/IL-17A axis has a pivotal role in the development of psoriasis, as evidenced by the high efficacy of biologic therapies targeting this pathway. 4 Notably, IL-17-induced genes in keratinocytes were highly enriched among FIG 5 . In vivo delivery of miR-146a alleviates psoriasiform skin inflammation. A, Experimental design for intradermal administration of miR-146a mimics (or scramble oligo controls) and imiquimod (IMQ) cream (Aldara) topical application on the back skin of WT mice. B, Quantification of skin thickness (left) and cumulative severity score (right; including scaling, skin thickness, and erythema) from WT mice on treatment with miR-146a mimic or controls (scrambled oligos; n 5 6). C, Macroscopic imaging, hematoxylin and eosin staining (left), and quantification of epidermal thickness (right) of IMQ-treated WT mice after intradermal injection of miR-146a mimic or scramble control (n 5 4). D, IHC for Ki67 (left) and quantification of Ki67 1 cells (right) in epidermis (n 5 4). E, Quantification of Gr-1 1 cells in back skin (n 5 4). F, qPCR analysis of miR-146a, Il1b, and Ly6G in samples obtained from IMQ-treated back skin of WT mice on intradermal injection of miR-146a mimic or scramble control (n 5 6). Scale bar 5 100 mm. *P < .05 and **P < .01.
the genes significantly altered in skin lesions of miR-146a-deficient mice compared with those of WT mice, indicating that the observed increased inflammation is at least in part due to increased activity of IL-17 signaling in keratinocytes. We demonstrate that miR-146a 2/2 keratinocytes had higher basal chemokine production and increased sensitivity toward IL-17 and that manipulation of the level of miR-146a in keratinocytes shifted their sensitivity toward IL-17. These results imply that in skin miR-146a acts as a counterbalance to restrain inflammation in response to IL-17 and that miR146a-deficient keratinocytes are primed for a strong IL-17 response. The level of miR-146a in relation to the inflammatory cytokine milieu can be important to define the threshold of inflammation in the skin. The protective effect of the CC genotype, which has previously been shown to be associated with higher miR-146a levels in skin, 24 might be explained by less sensitivity to IL-17-mediated skin inflammation in these subjects, whereas relatively lower levels of miR-146a in skin of subjects carrying the GG/CG genotype might be more susceptible to the disease as a consequence of increased inflammatory signaling caused by insufficient feedback suppression of the IL-17A signaling pathway.
A functional consequence of increased sensitivity of miR146a-deficient keratinocytes toward IL-17 is increased neutrophil chemoattraction. 33 Vice versa, injection of miR-146a mimics decreased neutrophil infiltration in the skin. Our results indicate that miR-146a acts as a break on neutrophil-keratinocyte crosstalk, reducing neutrophil influx by suppression of IL-17-induced epidermal chemokine production.
Hyperproliferation of keratinocytes in patients with psoriasis is a key feature of the disease. 3 Our results indicate that lack of miR146a primes the skin for epidermal hyperproliferation, even in the absence of imiquimod. miR-146a has been shown to regulate proliferation of keratinocytes in vitro by targeting EGFR, 24 and it has been observed in patients with another chronic inflammatory skin disease-model. 34 Regulation of IL-8 by miR-146a both in unstimulated cells and after exposure to IL-17A offers an additional mechanism because IL-8 is known to stimulate keratinocyte proliferation. 35 Overexpression of miR-146a in skin of patients with psoriasis is consistent with high levels of IL-17A, which induce its expression. Despite the anti-inflammatory effect of miR-146a, we see ongoing inflammation and an enhanced IL-17A signature in the epidermis of patients with psoriasis, indicating that miR-146a is not sufficient in itself to completely suppress drivers of psoriasis-induced inflammation. One potential mechanism for this can be that other drivers of inflammation override the suppressive effect of miR-146a; another possibility is the presence of genetic variations in the target genes of miR-146a, affecting miR146a-mediated regulation of these genes. Our results indicate that miR-146a contributes to defining the threshold of inflammatory response in the skin and can counterbalance the psoriasis-predisposing effect of psoriasis susceptibility genes or environmental factors to some extent.
In conclusion, our results identify miR-146a as an miRNA important for the development and maintenance of psoriasis, its levels affecting not only the severity but also the course of the disease. miR-146a acts as a potent suppressor of IL-17-driven skin inflammation, and its low levels might contribute to early disease onset in genetically susceptible subjects. Our results highlight the role for noncoding RNAs in psoriasis susceptibility and suggest miR-146a overexpression as a potential therapy approach.
